tetano
Editor, Senior Moderator
Open Forum Infect Dis
. 2022 Nov 8;9(11)
fac579.
doi: 10.1093/ofid/ofac579. eCollection 2022 Nov.
A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV
Helen M Chun[SUP] 1 [/SUP], Kyle Milligan[SUP] 1 2 [/SUP], Elfriede Agyemang[SUP] 1 [/SUP], Nathan Ford[SUP] 3 [/SUP], Ajay Rangaraj[SUP] 3 [/SUP], Shalini Desai[SUP] 4 [/SUP], Annelies Wilder-Smith[SUP] 4 [/SUP], Marco Vitoria[SUP] 3 [/SUP], Isaac Zulu[SUP] 1 [/SUP]
Affiliations
Abstract
HIV infection is a significant independent risk factor for severe coronavirus disease 2019 (COVID-19) disease and death. We summarize COVID-19 vaccine responses in people with HIV (PWH). A systematic literature review of studies from January 1, 2020, to March 31, 2022, of COVID-19 vaccine immunogenicity in PWH from multiple databases was performed. Twenty-eight studies from 12 countries were reviewed. While 22 (73%) studies reported high COVID-19 vaccine seroconversion rates in PWH, PWH with lower baseline CD4 counts, CD4/CD8 ratios, or higher baseline viral loads had lower seroconversion rates and immunologic titers. Data on vaccine-induced seroconversion in PWH are reassuring, but more research is needed to evaluate the durability of COVID-19 vaccine responses in PWH.
Keywords: COVID-19 vaccines; SARS-CoV-2 antibody; people with HIV; seroconversion.
. 2022 Nov 8;9(11)
fac579.doi: 10.1093/ofid/ofac579. eCollection 2022 Nov.
A Systematic Review of COVID-19 Vaccine Antibody Responses in People With HIV
Helen M Chun[SUP] 1 [/SUP], Kyle Milligan[SUP] 1 2 [/SUP], Elfriede Agyemang[SUP] 1 [/SUP], Nathan Ford[SUP] 3 [/SUP], Ajay Rangaraj[SUP] 3 [/SUP], Shalini Desai[SUP] 4 [/SUP], Annelies Wilder-Smith[SUP] 4 [/SUP], Marco Vitoria[SUP] 3 [/SUP], Isaac Zulu[SUP] 1 [/SUP]
Affiliations
- PMID: 36438620
- PMCID: PMC9685180
- DOI: 10.1093/ofid/ofac579
Abstract
HIV infection is a significant independent risk factor for severe coronavirus disease 2019 (COVID-19) disease and death. We summarize COVID-19 vaccine responses in people with HIV (PWH). A systematic literature review of studies from January 1, 2020, to March 31, 2022, of COVID-19 vaccine immunogenicity in PWH from multiple databases was performed. Twenty-eight studies from 12 countries were reviewed. While 22 (73%) studies reported high COVID-19 vaccine seroconversion rates in PWH, PWH with lower baseline CD4 counts, CD4/CD8 ratios, or higher baseline viral loads had lower seroconversion rates and immunologic titers. Data on vaccine-induced seroconversion in PWH are reassuring, but more research is needed to evaluate the durability of COVID-19 vaccine responses in PWH.
Keywords: COVID-19 vaccines; SARS-CoV-2 antibody; people with HIV; seroconversion.